Aims And Background: Recent publications of breast cancer classification based on gene expression profile analyses indicate that medullary breast carcinomas (MBC) may be considered part of the basal-like carcinoma spectrum made up of ER-negative, PR-negative and HER-2-negative cells ("triple-negative phenotype"). On the other hand, there are also data showing that a proportion of MBC and atypical MBC (AMBC) is ER, PR and/or HER-2 positive. Therefore, we have decided to immunohistochemically analyze ER, PR, HER-2 and basal/myoepithelial markers CK 5/6, p63 and EGFR expression in our archival paraffin-embedded MBC and AMBC samples from 48 patients.

Methods: Immunohistochemical evaluation of samples which were derived from patients operated on at our two hospitals between 1999 and 2005.

Results: Typical MBC was found in 39 patients and AMBC in 9 patients. The patients ranged in age from 32 to 84 years (median 55). Modified radical mastectomy with axillary dissection was performed in 30/48 patients (63%) while breast segmentectomy with axillary dissection was performed in 18/48 patients (37%). Metastases in axillary lymph nodes were observed in 15/48 patients (31%). ER positivity was present in 3/48 patients (6%), PR positivity in 8/48 (17%), and a positive HER-2 reaction was present in 14/48 patients (29%). CK 5/6 was positive in 20/48, p63 in 24/48 and EGFR in 8/48 patients. Adjuvant therapy was applied in all but 2 patients. Alive were 45/48 (94%) of patients. With the exception of PR expression, 39 patients with typical MBC and 9 patients with AMBC were comparable in the analyzed parameters. Positive HER-2 antigen expression in the analyzed sample was not found to be associated to a statistically significant degree with the MBC or AMBC histological tumor type, tumor size, axillary lymph node metastases, ER and PR status nor with patient survival.

Conclusions: The data from our study seem to be generally comparable with the relatively scarce published data on clinicopathological parameters of MBC and AMBC.

Download full-text PDF

Source
http://dx.doi.org/10.1177/030089160809400611DOI Listing

Publication Analysis

Top Keywords

mbc ambc
16
patients
14
5/6 p63
8
p63 egfr
8
antigen expression
8
medullary breast
8
breast cancer
8
mbc
8
typical mbc
8
mbc patients
8

Similar Publications

Expansion of atypical memory B cells (aMBCs) was demonstrated in malaria-exposed individuals. To date, the generation of P. vivax-specific aMBCs and their function in protective humoral immune responses is unknown.

View Article and Find Full Text PDF
Article Synopsis
  • Recent advancements in antibody-drug conjugates (ADCs) have improved outcomes for patients with HER2-low-expressing breast cancer, a group that previously lacked effective targeted therapies.
  • A systematic review and meta-analysis was conducted to evaluate the effectiveness of various ADCs, including trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in treating HER2-low advanced or metastatic breast cancer, pulling data from multiple reputable sources.
  • The findings revealed that patients treated with T-DXd had significantly better outcomes in terms of objective response rate, disease control rate, and overall survival compared to those receiving traditional treatment options, highlighting the potential of ADCs as effective therapies.
View Article and Find Full Text PDF

Drug release kinetics from in-situ modulated agar/chitosan-bacterial cellulose patches for differently soluble drugs.

Int J Biol Macromol

December 2024

Cellulose & Composites Research Group, Department of Materials Science and Metallurgical Engineering, Indian Institute of Technology, Hyderabad, Kandi, 502285 Sangareddy, Telangana, India. Electronic address:

Bacterial cellulose (BC) stands out as a promising candidate for novel drug delivery systems due to its micro-mesoporous nanofibrous interconnected structure. However, its performance is limited by the burst release of hydrophilic drugs and lower incorporation of the less water-soluble or insoluble drugs. In this study, we explored its potential as a drug carrier for two distinct types of drugs: Diclofenac sodium and Simvastatin, representing water-soluble and water insoluble compounds, respectively.

View Article and Find Full Text PDF

Background: Palbociclib in combination with endocrine therapy is approved for treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. In addition to clinical trials, several real-world studies have evaluated the effectiveness of palbociclib. With increased life expectancy in the general population, breast cancer in older women is also expected to increase.

View Article and Find Full Text PDF
Article Synopsis
  • This study assessed the cost-effectiveness of elacestrant (ELA) versus standard-of-care (SOC) for advanced or metastatic breast cancer in the US, examining patients who had already received treatment.
  • The analysis used a 10-year health outcomes model and incorporated data from a clinical trial, adjusting for costs and health utilities impacting quality-adjusted life years (QALYs).
  • Results showed ELA had significantly high costs per QALY gained, exceeding the typical willingness-to-pay threshold, indicating that it is not cost-effective compared to SOC for this patient population.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!